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Elfect of glucose on the function of the calcitriol receptor and vitamin
D metabolism. The genomic action of calcitriol is mediated through the
interaction of the calcitriol receptor (VDR) with vitamin D response
elements (VDREs) of the target genes. It has been proposed that
chemicals capable of Schiff base formation with the VDR potentially could
alter the physiological function of VDR and calcitriol metabolism. Since
glucose has been shown to form Schiff bases with proteins, we tested the
hypothesis that glucose could influence the function of VDR and thereby
alter calcitriol metabolism. Glucose 6-phosphate inhibited VDR binding
to the osteocalcin VDRE and chemically modified the DNA binding
domain or the dimerization domain of the VDR in Vitro. Further, glucose
also blocked the production of chioramphenicol acetyltransferase (CAT)
enzyme induced by calcitriol in cells transfected with a constructed VDRE
attached to a CAT reporter gene. Hyperglycemia induced by glucose
infusion or by streptozotocin in normal rats significantly reduced intestinal
10, 25-dihydroxyvitamin D-24-hydroxylase activity. Taken together, these
findings are consistent with the hypothesis that glucose could interact with
the VDR to impair its DNA binding and function within cells.
Most of the biological actions of calcitriol are receptor-medi-
ated processes. The hormone-receptor complexes interact with
vitamin D response elements (VDREs) and thus regulate the
transcription of those genes. Therefore, inhibition of the hor-
mone-receptor complexes binding to the VDREs will impair
transcription of the target genes. Pyridoxal 5 '-phosphate forms
Schiff bases with the DNA binding domain of steroid receptors
and inhibits the receptor's interaction with DNA-cellulose [1—4].
It also inhibited VDR binding to VDRE in vitro and impaired the
transcription of the gene [5]. Thus, chemical compounds capable
of Schiff base formation with VDR potentially could alter the
physiological function of VDR and calcitriol metabolism. Since
glucose has been shown to form Schiff bases with proteins [6, 7],
we tested the hypothesis that glucose could influence the function
of VDR and thereby alter calcitriol metabolism. In this study, we
examined the effects of glucose on VDR binding to VDRE in vitro
and on the transcription of a reporter gene in vivo using tran-
siently transfected JEG-3 cells. In addition, we examined the
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effects of hyperglycemia on the synthesis of la,25-dihydroxyvita-
mm D-24-hydroxylase (24-hydroxylase) in animals, because the
synthesis of this enzyme is a VDR regulated process [81.
METHODS
Electrophoretic mobility shift assay (EMSA) of intestinal VDR
or recombinant VDR incubated with glucose 6-phosphate
VDR binding to osteocalcin YDRE. (a) Preparation of intestinal
I/DR. Rats were decapitated and the initial 20 cm of small
intestine distal to the pylorus (duodenum and portion of jejunum)
was removed and flushed with ice cold Ca/Mg-free phosphate (6.6
mM Na2HPO, 250 lU/mi Trasylol and 1.5 mrvi KH2PO4)-buffered
saline (CMF-PBS). The mucosal cells were scraped from the
serosa, washed three times in 20 volumes of CMF-PBS and
centrifuged at 200 x g for five minutes after each washing. The
tissue was homogenized by a Polytron in 20 vol (wt/vol) of buffer
consisting of 200 jig/mI soybean trypsin inhibitor, 10 mrvt Tris-HC1
(pH 7.4), 1 mivi EDTA, 10 m sodium molybdate, 5 mM dithio-
threitol and 300 mivt KC1 (KTED) [9]. Cellular protein was
prepared by centrifugation at 100,000 X g for 45 minutes at 0 to
4°C and the supernatant containing the VDR was used for the
following study.
(b) Electrophoretic mobility shift assay (EMSA). A 36 base pair
synthetic oligonucleotide encompassing the rat osteocalcin gene
VDRE (base pairs —459 to —432 with CTAG overhangs [10]) was
labeled by a fill-in reaction using the Klenow fragment of DNA
polymerase I and [a-32PjdCTP. The labeled DNA probe was
purified on a Sephadex G-50 column.
Intestinal cellular proteins (15 j.tl or approximately 40 jig
cellular protein) were incubated for one hour with various con-
centrations of glucose 6-phosphate [0, 5, 15 and 50 m in TED
buffer, pH 6.6 (KTED buffer without 300 mM KCI)]. Thereafter,
the proteins were incubated for another 15 minutes in 35 p1 of
mobility shift reaction buffer containing 5 mrvt Tris, 15 miss Hepes,
3.5 miss MgCl2, 5 mist EDTA, 10% glycerol, 0.1% Tween 20, 5 m
dithiothreitol, 0.15 jig poly(dI-dC), and 100 miss KCI, pH 7.9 [11].
At the end of this incubation, approximately 15,000 to 30,000 cpm
of radiolabeled osteocalcin VDRE probe was added in each
mobility shift reaction mixture. The reaction mixtures were gently
vortexed, incubated for another 10 minutes and electrophoresed
on 6% nondenaturing polyacrylamide gels at 100 V for approxi-
mately three hours. The mobility shift running buffer contained 50
mM Tris, 380 mM glycine, and 2 miss EDTA (pH 8.5) [12]. The
dried gel was autoradiographed, and the free and VDR-bound
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VDREs were quantified by excising the appropriate portions of
the gel followed by liquid scintillation counting.
VDR binding to the osteopontin J/DRE. Preparation of a truncated
VDR. We produced a truncated VDR (amino acids 1-119) that
lacks the ligand binding domain. The PCR-based splicing by
overlap extension technique was used to place a stop codon after
amino acid 119 with a standard protocol and expressed in an E.
coli expression plasmid vector pMalc2 (New England Biolabs).
This vector produces a fusion protein of maltose binding protein
followed by a cleavage site for factor Xa and the recombinant
truncated VDR. The fusion proteins of VDR were purified by
affinity chromatography [131. The truncated VDR includes the full
zinc fingers, T (which is the connector between the A-helix and
the DNA binding domain) and A [A-helix, which is corresponding
to the A box of nerve growth factor inducible-B (NGFI-B)] box
domains [14], but lacks the ligand binding domain.
A 32 bp synthetic oligonucleotide encompassing the rat os-
teopontin gene VDRE (bp —761 to —738 plus GATC overhangs
[15]) was labeled by a fill-in reaction and used as a probe. EMSA
incubations utilized approximately 10 g of the truncated VDR.
Receptors were incubated individually for one hour at 15°C with
0 or 5 m glucose 6-phosphate. Thereafter, these receptor
preparations were added to EMSA incubations as described
above.
Effect of glucose on calcitriol-dependent expression of a
reporter gene in transfected JEG-3 cells
We used transiently transfected JEG-3 cells to study the effect
of glucose on calcitriol induction of a reporter gene [12]. The
human VDR cDNA was expressed from the vector pCDM. The
reporter plasmid was derived from pUTKAT3 [15], and contained
two copies of the sequence 5'-GATCCACTAGGTCAAGGAG-
GTCATGGATC ligated 5' to the basal thymidine kinase pro-
moter driving expression of chioramphenicol acetyltransferase
(CAT) (pTKD2AA). An internal control plasmid expressing
human growth hormone (OH) from the basal thymidine kinase
promoter (pTKGH) was utilized to control for transfection effi-
ciency. Transfections included 4 jtg of pTKD2AA, 10 ng of
pCDMVDR, 1 tg of pTKGH, and 6 g of pCDM as filler plasmid
per 60 mm Petri dish. Cells were cultured with or without 100 nrvi
calcitriol and glucose was added to the culture medium (contain-
ing 100 mg/dl glucose) with a final concentration of 550 mgldl for
96 hours. The medium was changed once at 48 hours. Ninety-six
hours after the incubation, cell lysates were analyzed for CAT
activity and media for human GH as described [16]. In control
studies, cells were cultured in the media containing mannitol 450
mg/dl and 100 mg/dl glucose 100 nM calcitriol for 96 hours. The
medium was changed once at 48 hours. Fold CAT induction is
defined as CAT/human OH for cells cultured with calcitriol
divided by CAT/human OH for cells cultured without calcitriol.
Intestinal 24-hydroxylase activity in normal rats infused with
glucose
Normal Sprague-Dawley rats (200 to 215 g) fed with regular
Purina rat chow containing 1.0% Ca, 0.8% F, and 4.5 IU per g
vitamin D were used throughout the study. On the day of
experimentation, rats were weighed and anesthetized with ether.
The femoral artery and vein were cannulated with polyethylene
tubing (FE) for blood sampling and fluid infusion. A PE 50 tube
was inserted into the bladder for urine collection. The animals
were placed in individual cages and infused intravenously with
15% glucose solution for 24 hours and delivered glucose 4 g/100
g body wt (N = 5). Control animals (N = 6) were infused with 50
to 60 ml normal saline. At the end of the infusion, arterial blood
was withdrawn for measurements of plasma concentrations of
glucose and calcitriol. Animals were killed and intestinal 24-
hydroxylase activities were measured 24 hours after the infusion.
Metabolic clearance rate (MCR) of calcitriol and 24-
hydroxylase activity in diabetic rats induced by streptozotocin
Normal Sprague-Dawley rats (210 to 230 g) were injected with
60 mg/kg streptozotocin (dissolved in sodium citrate buffer solu-
tion, pH 4.5) through the tail veins. Control animals were injected
with the vehicle. Five days after streptozotocin or saline injection,
animals were weighed and anesthetized with ether. The femoral
artery and vein were cannulated with polyethylene tubing (PE) for
blood sampling and fluid infusion. A PE 50 tube was inserted into
the bladder for urine collection. The animals were placed in
individual cages for the following experiments.
Both streptozotocin injected (N = 5) and saline injected
animals (N = 5) were infused intravenously for 24 hours 60 ml
saline solution containing 0.05 jtCi of radiolabeled calcitriol
(la,25 [26, 27(n]-3H] dihydroxyvitamin D3,160 Ci/mmol; New
England Nuclear). The metabolic clearance of calcitriol detailed
in a previous communication [17] was determined 18 and 20 hours
after the infusion.
Arterial blood samples (0.5 ml) were drawn 18 and 20 hours
after the fluid infusion and the plasma concentrations of radioac-
tive calcitriol were determined [17]. Our intra-assay and interassay
coefficients of variation for radioactive calcitriol were 6.8% and
6.7%, respectively. Since there was no difference in the calculated
MCR at 18 and 20 hours, only the average values of the MCR
were presented in this study. At the end of infusion, arterial blood
was obtained for the measurement of calcitriol, calcium, phospho-
rus, and creatinine. Animals were fasted during the infusion.
The MCR of calcitriol was calculated as [17]:
MCR = Infusion rate of 3H-calcitriol
The mean steady state plasma concentration of 3H-calcitriol
The production rate (PR) of calcitriol was calculated as:
PR = MCR x endogenous plasma concentration of calcitriol
Intestinal calcitriol receptor in diabetic rats induced by
streptozotocin
Normal Sprague-Dawley rats (200 to 230 g) were injected with
60 mg/kg streptozotocin through the tail veins. Control animals
were injected with normal saline. Five days after streptozotocin or
saline injection, animals were weighed and anesthetized with
ether. Rats were decapitated and the initial 20 cm of small
intestine distal to the pylorus (duodenum and portion of jejunum)
was removed and flushed with 30 ml ice-cold Ca/Mg-free phos-
phate (6.6 mM Na2HPO4, 250 lU/mi Trasylol and 1.5 mM
KH2PO4)-buffered saline (CMF-PBS). The mucosal cells were
scraped from the serosa, washed three times in 20 volumes of
CMF-PBS and centrifuged at 200 >< g for five minutes after each
washing. The tissue was homogenized by a Polytron in 20 vol
(wt/vol) of buffer consisting of 300 mrvi KC1, 400 jig/mI soybean
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trypsin inhibitor, 250 lU/mi trasylol, 10 m sodium molybdate, 10
mM Tris-HCI (pH 7.4), 1 mai EDTA, and 5 mivi dithiothreitol
(KTED) [18]. Cytosol was prepared by centrifugation at
100,000 x g for 45 minutes at 0 to 4°C. Cytosol protein concen-
tration was determined by the Bradford method [19].
Calcitriol receptor concentration was measured by equilibrium
binding. Cytosol preparations were approximately 2 to 4.5 mg/mi
of protein prior to the binding assay. Approximately 0.2 to 0.4 mg
cytosol protein in KTED buffer (100 jil) was incubated with 5 mst
tritiated calcitriol (la,25-[3H-26,27-]-dihydroxyvitamin D3, 160
Ci/mmol specific activity; New England Nuclear, Boston, MA,
USA) for three hours at 2°C [18]. For estimation of nonsaturable
binding, a 100-fold molar excess of unlabeled calcitriol was added
in addition to the tritiated calcitriol to a separate set of incubation
tubes. Bound hormone was separated from free hormone by
adsorption of free hormone to dextran-coated charcoal (0.2%
dextran, 2.0% charcoal in 10 mM Tris-HC1, 1.0 mrvi EDTA, pH
7.4) for 15 minutes. on ice, followed by centrifugation at 1,600 X
g. Supernatants were counted with a scintillation counter. Specific
binding of calcitriol was calculated by subtracting nonspecific
binding from total binding [18].
Analytical methods
Calcium was measured with an atomic absorption spectropho-
tometer (Model 306; Perkin Elmer, Norwalk, CT, USA). Creati-
nine was measured as described previously [17]. Glucose concen-
trations were determined by the glucose oxidase method (Sigma,
St. Louis, MO, USA). Plasma calcitriol was measured in duplicate
according to the methods of Reinhardt et al [20] and Hollis [21].
Our interassay coefficients of variation were 7.0% for low control
(20 pg!ml, N = 12) and 4.1% for high control (100 pg/mI, N = 12).
The intra-assay coefficients of variation were 5.4% for low control
(N = 6) and 4.7% for high control (N = 6), respectively. Calcitriol
recovery averaged 65%.
Intestinal 24-hydroxylase activity (assessed by conversion of
calcitriol to 1,24,25(OH)1D3 was measured according to previ-
ously described methods [22]. The intestinal mucosa was scraped
and homogenized in ice-cold 0.25 M sucrose solution to yield a 2%
wt/vol homogenate. One milliliter of the homogenate was placed
in a 25 ml Erlenmeyer flask. To each of the flasks we added 0.5 ml
of Buffer I (22 mrvi glucose-6-phosphate, 20 mivi ATP disodium
salt, 160 miu nicotinamide, 0.42 msi NAD, 0.37 mrvi NADP, 7.5
mM succinate, 0.1 M K2HPO4, pH 7.4) and 0.5 ml of Buffer II (5
mM MgCl2, 0.1 M KC1, 0.2 units/mI glucose-6-phosphate dehydro-
genase, 0.85 units/ml alcohol dehydrogenase). Vitamin D binding
protein of the homogenates was saturated with 50 .tM vitamin D3,
so that calcitriol added to the medium remained free from protein
binding [23]. The mixture, open to the atmosphere, was incubated
and agitated (100 cycles/mm) at 37°C. The reactions were termi-
nated two minutes after incubating with the substrates by the
addition of 10 ml methanol:chloroform (2:1). 24-Hydroxylase
activity was expressed as the total generation of 1,24,25(OH)3D3
pmol per mg of intestinal mucosa in two minutes. Five micro-
grams of cold 1,24,25(OH)3D3 were added to each flask for
subsequent recovery measurements during the extraction of the
trihydroxyvitamin D metabolite.
The extraction of radiolabeled 1,24,25(OH)5D1 from incuba-
tion medium was identical to that described previously [22].
Briefly, the reaction was terminated by the addition of methanol:
chloroform and the flask contents were decanted into 50 ml
separatory tubes. Three ml of homogenizing buffer and four ml
chloroform were added to each tube. The mixture was vigorously
vortexed for 20 seconds and centrifuged at 200 g for 15 minutes.
The upper aqueous phase was removed and the lower organic
phase containing lipids was aspirated and placed into 15 ml tubes.
The chloroform was evaporated with nitrogen gas. The pellet was
reconstituted in one ml hexane: methanol:chloroform (9:1:1) and
applied to a Sephadex LH 20 column (0.6 cm X 15.5 cm). The
column was washed with 18.0 ml of hexane:methanol:chloroform
(9:1:1) and the eluate was discarded. The column was then washed
with 11.0 ml of hexane:methanol:chloroform (8:2:2). The eluate
was collected into 15 ml tube. The hexane:methanol:chloroform
was evaporated under nitrogen gas. The extract was reconstituted
in 0.5 ml 86:14 hexane: isopropanol and injected into a Zorbax Sil
silicic acid Dupont Column developed in 86:14 hexane:isopropa-
nol. The tritiated trihydroxyvitamin D metabolite was isolated
using HPLC, mixed with organic phase scintillation liquid and
counted (Packard Scintillation Counter, model 3255; Packard
Instrument, Downers Grove, IL, USA). The trihydroxyvitamin D
metabolite was quantitated by multiplying the ratio of tritiated
trihydroxyvitamin D metabolite to tritiated calcitriol with the
amount of cold calcitriol added to the reaction mixture.
RESULTS
Effect of glucose 6-phosphate on VDR binding to osteocalcin
and osteopontin VDRE
As shown in Figure 1, intestinal VDR incubated with 5 mi
glucose 6-phosphate had significantly lower binding affinity for
osteocalcin VDRE compared to VDR either incubated with or
without 5 ms'i mannitol. The truncated VDR (119 amino acids)
also had decreased binding affinity for osteopontin VDRE when it
was pre-incubated with 5 m glucose 6-phosphate for one hour
(Fig. 2). This indicates that glucose-6-phosphate interacts with the
VDR DNA binding domain, not the ligand binding domain.
The effect of glucose 6-phosphate on the intestinal VDR-
osteocalcin VDRE interaction is quantified in Figure 3. Mannitol,
even up to 50 mM, did not impair the VDR-VDRE complex.
However, glucose 6-phosphate inhibited the interaction of the
VDR with the osteocalcin VDRE in a dose related manner.
Effect of glucose on calcitriol-dependent expression of a
reporter gene in transfected JEG-3 cells
JEG-3 cells were transiently transfectcd with a VDR expression
plasmid, a VDRE-containing CAT reporter plasmid, and an
internal control plasmid expressing human GH. In the absence of
transfected VDR, calcitriol did not induce CAT (average 0.99-
fold, N = 4). However, following cotransfection with the expres-
sion vector pCDMVDR, calcitriol induced CAT activity 26.9-fold
(Fig. 4, control bar). Addition of glucose (550 mg/dl) inhibited
approximately 21% of calcitriol-induced CAT activity (21.3-fold),
whereas addition of mannitol (450 mg/dl mannitol + 100 mg/dl
glucose) did not affect the expression of CAT induced by calcitriol
(Fig. 4). Furthermore, this effect of glucose was on the calcitriol-
induced activity, not the basal CAT activity (control basal CAT
activity, 4.50 0.15%, mannitol, 4.43 0.10%, glucose, 5.8
0.60%, all P = NS) or human GH expression (control basal
secretion, 3.02 0.25 nglml, mannitol, 3.47 0.21 ng/ml, glucose,
2.92 0.50 ng/ml, all P = NS).
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Fig. 1. Inhibition of intestinal VDR-osteocalcin VDRE complex by glu-
cose-6-phosphate. Intestinal VDRs were incubated for one hour with 5
mM pyridoxal 5-phosphate, glucose-6 phosphate or mannitol and then
incubated with labeled VDRE. Lane 1, incubation of VDR with labeled
VDRE to demonstrate the VDR-VDRE complex (arrow); addition of 100
fold non-radiolabeled VDRE (lane 2) or pyridoxal 5'-phosphate (lane 3)
to the mixtures eliminated the VDR-VDRE complexes; lane 4, mannitol
did not inhibit the VDR-VDRE complex; lane 5, addition of glucose-6-
phosphate diminished the VDR binding to the VDRE.
Intestinal 24-hydroxylase activity in normal rats infused with
glucose
The effect of glucose infusion (4 gIlOO g body wt124 hr) on
24-hydroxylase activity and plasma calcitriol concentrations are
presented in Table 1. Plasma calcitriol levels were increased
following elevation of plasma glucose concentrations in glucose
infused rats, while intestinal 24-hydroxylase activities were signif-
icantly suppressed when compared to the control saline infused
rats.
Metabolic clearance rate (MCR) of calcitriol and 24-
hydroxylase activity in diabetic rats induced by streptozotocin
Plasma concentrations of glucose, creatinine, calcium, phos-
phorus, calcitriol, MCR, PR and 24-hydroxylase activity are
— + +
— 0mM 5mM
1 2 3
Fig. 2. Inhibition of truncated VDR (VDR DNA binding domain) binding
to radiolabeled osteopontin VDRE by glucose-6-phosphate.
summarized in Table 2. Streptozotocin injected rats had signifi-
cantly higher plasma concentrations of glucose; however, plasma
creatinine, calcium and phosphorus were not different from the
controls. Plasma concentration of calcitriol and production rate of
calcitriol were decreased in streptozotocin induced diabetic ani-
mals. In addition, MCR was significantly decreased in diabetic
rats. The latter is consistent with the lower values of 24-hydroxy-
lase activities in diabetic animals (Table 2).
Intestinal calcitriol receptor in diabetic rats induced by
streptozotocin
Table 3 summarizes plasma concentrations of glucose and
calcitriol and intestinal concentrations of VDR in streptozotocin
injected rats. Intestinal concentrations of VDR were determined
five days after injection of saline (N = 6) or streptozotocin (N =
6). The values of VDR were significantly lower in diabetic rats
when expressed as fmol specific binding of calcitriol/mg protein.
VDR +
Cold VDRE -
Pyridoxine —
Mannitol —
G-6-P04 —
lane 1
+ + + +
+
— 5mM —
— — 5mM
VDR
G-6-P04
lane
a—
P<OO5
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Control Mannitol Glucose
(N=5) (N=4) (N=5)
Fig. 4. Effect of glucose on the expression of calcitriol-induced CAT
activity in transfected JEG-3 cells. JEG-3 cells were transfected with a
VDR expression vector, a CAT reporter plasmid driven by a calcitriol
responsive promoter, and a human growth hormone (GH)-expression
reporter as an internal control. Cells were incubated with glucose (450
mgldl + medium glucose 100 mg/dl) or mannitol (450 mg/dl + medium
100 mg/dl glucose), in each case with or without 100 nM calcitriol, for 96
hours. Fold CAT induction is defined as CAT/human GH for cells
cultured with calcitriol divided by CAT/human GH for cells cultured
without calcitriol (*P < 0.05).
Table 1. Effect of glucose infusion on plasma calcitriol and intestinal
24-hydroxylase activity
Experiments
Plasma
glucose
mg/dl
Plasma
calcitriol
pg/mi
l,24,25(OH)3D3a
pmol/mg
tissue/mm
4.12 0.10Saline infusion 146.2 5.0 88.1 2.98
(N = 5)
Glucose infusion 244.0 7.2 158.1 7.30 2.34 0.15
(N =5)
P value 0.001 0.001 0.001
a 24-hydroxylase activity was determined by measuring the conversion of
1,25(OH)7D3 to 1,24,25(OH)3D3. Intestinal mucosa was incubated with
1,25(OH)2D3 for 2 mm.
response elements. A recent study, however, indicated that chem-
ical modification of lysines located at positions 360 and 365 of the
hormone binding domain interferes with human retinoic acid
receptor a (hRARcw) dimerization with retinoid X receptor a
(hRXRa) [27]. In VDR asparagine, glutamic acid, lysine and
arginine located in T and A box domains are important for
dimerization and DNA binding [14]. Since the truncated VDR
contains T and A box domains, modification of these amino acids
may impair the function of the VDR as well. We hypothesize that
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Fig. 3. Percent inhibition of VDR binding to the VDRE by increasing
concentrations of glucose-6-phosphate (•, N = 4) and mannitol (0, N =
4).
However, when the concentration of VDR was expressed as
fmol/100 j.tl of intestinal homogenate, the cellular binding affinity
for 3H-calcitriol in diabetic animals was not different from that of
control rats. The reason is that intestinal concentrations of
proteins were significantly higher in diabetic rats than in the
controls (0.42 0.01 mgJlOO jiJ vs. 0.27 0.01 mgIlOO i.tl, P <
0.001). Plasma glucose was elevated and plasma calcitriol was
lower in diabetic rats as above.
DISCUSSION
Nonenzymatic glycosylation of proteins has been well estab-
lished. Glucose reacts with the N-terminal valine of the hemoglo-
bin A j3 chain to form hemoglobin A1 [24], and also reacts with
lysine c-amino groups of numerous proteins such as albumin [7].
Glucose-6-phosphate appears to be more active than glucose in
vitro [25]. In these reactions the carbohydrate-carbonyl moiety
first forms a Schiff base with the protein amino group and
subsequently undergoes Amadori rearrangement [24].
Pyridoxal 5'-phosphate also contains a reactive aldehyde group
and appears to form Schiff bases with steroid receptors and inhibit
receptor interaction with DNA-cellulose [1—41. Steroid receptor
superfamily members share structural homology in their DNA
binding domains. The DNA binding domain has two zinc fingers
that contain eight conserved cysteine residues and two zinc
molecules. The cVDR DNA binding domain has seven lysine
residues, three of which are highly conserved [26]. It has been
proposed that the aldehyde of the pyridoxal 5'-phosphate reacts
with the c-amino group of lysine within the steroid receptors'
DNA binding domain [1—4]. The formation of a Schiff base
interferes the interaction of the DNA binding domain with DNA
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Table 2. Plasma concentrations of glucose, creatinine, calcium, phosphorus, calcitriol, MCR, PR and 24-hydroxylase activity in diabetic rats
induced by streptozotocin
Exp.
Weights
g
'G Cr ')p p11
pg/mi
MCR
mi/mm/kg
PR
ng/kg/day
1,24,25(OH)3D3
pmol/mg tissue/mmmg/dl
Controls 256 2.9 162 5.85 0.72 0.02 9.62 0.09 6.84 0.39 94.5 1.1 0.28 0.003 37.5 0.5 4.42 0.19
N= 6
Diabetics 226 3.8 472 5.34 0.73 0.02 9.64 0.08 6.83 0.28 65.3 2.2 0.21 0.005 20.5 1.0 2.98 0.13
N= 5
P value 0.01 0.001 NS NS NS 0.001 0.001 0.001 0.001
Abbreviations are: P0, plasma glucose; Cr, plasma creatinine; RCa, plasma calcium; P, plasma phosphorus; Pcalcitrioi, plasma calcitriol; MCR,
metabolic clearance rate of calcitriol; PR, production rate of calcitriol.
24-Hydroxylase activity was determined by measuring the conversion of 1,25(OH)2D3 to 1,24,25(OH)3D3. Intestinal mucosa was incubated with
l.25(OH)2D3 for 2 mm.
Table 3. Plasma Concentrations of glucose and calcitriol and intestinal
concentrations of VDR in streptozotocin injected rats
Weight P0 calcitrioI VDR VDR
Exp. g mg/di pg/mi finol/mg fmoi/100 d
Controls 271 4.5 163 3.7 91.1 1.9 1122 14.1 101 3.4
N= 6
Diabetics 226 3.5 469 7.0 64.3 2.7 755 13.6 106 2.6
N= 6
P value 0.001 0.001 0.001 0.001 NS
Abbreviations are in Table 2. VDR was expressed as either fmol/mg
intestinal cellular protein or fmol/100 l intestinal cellular homogenate.
glucose could form Schiff bases with lysine amino acids in the
VDR DNA or hormone binding domain and impair its binding
affinity for VDREs directly or indirectly by interfering with
dimerization of receptor protein with nuclear auxiliary proteins.
In this study, we have demonstrated in vitro that glucose
6-phosphate inhibited VDR binding to the osteocalcin VDRE in
a dose dependent manner. Further, we have also shown that
glucose 6-phosphate inhibited the binding of a truncated VDR in
the absence of RXR to the osteopontin VDRE. Since the
truncated VDR contains the VDR DNA binding domain and
lacks the hormone binding domain, inhibition of the binding
suggests that the glucose 6-phosphate alters the DNA binding
domain of the VDR.
Although the effect of glucose 6-phosphate on the binding of
the VDR to the VDREs is dose-dependent, it should be cautioned
that the concentration of glucose 6-phosphate used in the EMSA
is several-fold higher than that of in vivo. Therefore, it is difficult
to extrapolate the results of the in vitro study to explain its actual
effects in vivo. If glucose 6-phosphate could chemically modify the
VDR in vitro, we predict that glucose might also alter the VDR in
vivo. To test this supposition, we employed transiently transfected
JEG-3 cells [121 to study the effect of glucose on calcitriol induced
transcription. We showed that high concentration of glucose
indeed impairs the ability of calcitriol to induce the expression of
a target gene. Therefore, our results are in agreement with the
hypothesis that glucose could interact with the VDR to impair its
DNA binding within cells.
To further study the effect of glucose in vivo, we examined the
effect of hyperglycemia on the in vivo activity of 24-hydroxylase, an
enzyme that is induced at transcriptional level by calcitriol [8, 28,
29]. We found that infusion of glucose into normal rats indeed
significantly reduced the activity of 24-hydroxylase. One possible
explanation is that hyperglycemia could chemically modify the
VDR in vivo and inhibits its function. The decreased activity of
this calcitriol degradation enzyme accounted for the elevation of
plasma calcitriol in hyperglycemic animals.
Since hyperglycemia is the primary disorder in diabetes, we
studied calcitriol metabolism in streptozotocin induced diabetes.
We have confirmed the previous findings of decreased calcitriol
synthesis in this model of diabetes. Administration of insulin in
this model of diabetes restores calcitriol production. Apparently,
insulin is required for the normal activity of 25-hydroxyvitamin D
lcs-hydroxylase [30]. In addition, we have shown that intestinal
24-hydroxylase activity is decreased in this model of diabetes and
others have also found decreased 24-hydroxylase activity in dia-
betic db/db mice as well [31]. The decreased activity of 24-
hydroxylase could account for decreased plasma concentrations of
24,25(OH)2D3 reported in streptozotocin induced diabetes [32]
and human diabetes [33]. Since 24-hydroxylase is one of the major
degradation enzymes of calcitriol, the metabolic clearance rate of
calcitriol in streptozotocin induced diabetic rats is slower than that
of the controls. Others have found no difference in plasma
disappearance of radiolabeled calcitriol in streptozotocin induced
diabetes [30] or increased metabolic clearance of calcitriol in
diabetic BB rats by the constant infusion of isotope technique
[34]. The discrepancy of calcitriol degradation between this report
and previous studies could be due to different methods [30] or
different models of diabetic animals used in the studies [34].
There are several reasons for the decreased enzymatic activity
of 24-hydroxylase in streptozotocin induced diabetes. (1) De-
creased calcitriol synthesis could slow down the degradation of
calcitriol, as calcitriol is known to up-regulate 24-hydroxylase [81.
(2) Decreased VDR concentrations may diminish the biological
response to calcitriol and reduce the synthesis of 24-hydroxylase
[8]. In the present study, we have found that intestinal VDR was
decreased when the specific calcitriol binding activity was ex-
pressed per mg intestinal cellular protein. However, when the
binding activity was expressed per 100 jrl of intestinal tissue
homogenate, there was no difference in the receptor numbers.
This is because the homogenates of the diabetic animals had
higher protein concentrations. Previous studies have demon-
strated that hypertrophy of the intestinal mucosa occurs in
streptozotoein induced diabetes [35]. Since we extracted the same
length (20 cm) of intestinal mucosa from both groups of animals,
we believe that expression of receptor number per 100 jid homog-
enate more accurately reflects the total number of VDR in the
intestine. Thus, decreased VDR concentrations could not account
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for decreased 24-hydroxylase activity in streptozotocin induced
diabetes. (3) The expression of calcitriol induced 24-hydroxylase
activity is a VDR mediated process [8, 36, 37]. The VDR interacts
with nuclear chromatin of target organs and activates the tran-
scription of specific genes to produce 24-hydroxylase. Therefore,
if the function of the VDR is altered, the production of 24-
hydroxylase will diminish. We have demonstrated that glucose
could reduce the binding of VDR to the VDRE and that high
concentrations of glucose impaired the ability of calcitriol to
induce the expression of a target gene in transfected JEG-3 cells.
Thus, our results are consistent with the hypothesis that high
concentration of glucose interacts with VDR to impair its DNA
binding within cells and reduces the synthesis of 24-hydroxylase.
Finally, there is considerable evidence that diabetic patients
suffer from decreased bone mass [38]. Abnormal mineral metab-
olism and decreased bone mass can be reproduced in various
models of experimental diabetes [39, 40]. Duodenal calbindin [39]
and plasma osteocalcin levels [38] have been reported to be lower
in diabetic animals. Osteocalcin is also reported to be lower in
human non-insulin dependent diabetes [38]. Therefore, abnormal
vitamin D metabolism could partly account for the pathophysiol-
ogy of decreased bone mass and impaired bone formation in
diabetes [40, 41].
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